<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04001530</url>
  </required_header>
  <id_info>
    <org_study_id>156-2019</org_study_id>
    <nct_id>NCT04001530</nct_id>
  </id_info>
  <brief_title>Half-normal Saline in Atrial Flutter Ablation</brief_title>
  <official_title>Verification of Half Normal Saline as a Superior Irrigant in the Catheter Radiofrequency Ablation of Typical Cavotricuspid Isthmus Dependent Atrial Flutter: A Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the acute and long-term efficacy of half-normal saline compared to normal saline
      for irrigation of open-irrigated catheters during catheter ablation for the treatment of
      cavotricuspid isthmus dependent atrial flutter.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is unclear whether ionic strength affects energy delivery and ablation lesion size during
      radiofrequency ablation for atrial flutter. Given that saline contains ionic sodium and
      chloride in the solution, it has conductive properties that may disperse radiofrequency
      energy away from the tip-tissue interface, thereby reducing current density and lesion size
      compared to ablation with nonionic solutions. The efficacy of half-normal saline will be
      measured by the time taken to create bidirectional block across the cavotricuspid isthmus as
      well as the acute recurrence rate within 30 minutes of the initial occurrence of
      bidirectional block and the 1 year freedom from flutter recurrence.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time taken to produce bidirectional block</measure>
    <time_frame>intraprocedural</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute recurrence rate &lt; 30 minutes of initial occurrence of bidirectional block</measure>
    <time_frame>intraprocedural</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from atrial flutter recurrence</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time taken for termination of atrial flutter</measure>
    <time_frame>intraprocedural</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total radiofrequency ablation time and procedural time</measure>
    <time_frame>intraprocedural</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of procedure-related complications</measure>
    <time_frame>at the time of the procedure and up to 1 month</time_frame>
    <description>pericardial effusion due to cardiac perforation or pericarditis, transient ischemic attack/stroke, systemic embolism, phrenic nerve injury, pulmonary vein stenosis, atrio-esophageal fistula, death</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of steam pops</measure>
    <time_frame>periprocedural</time_frame>
    <description>marker of excessive heating of the tissue</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Atrial Flutter</condition>
  <arm_group>
    <arm_group_label>Half-normal saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of half-normal saline (0.45% NaCl) as an irrigant for open-irrigated ablation catheters</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Use of normal saline (0.9% NaCl) as an irrigant for open-irrigated ablation catheters</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Half Normal Saline 0.45% Infusion Solution Bag</intervention_name>
    <description>Randomization to half normal saline</description>
    <arm_group_label>Half-normal saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline 0.9% Infusion Solution Bag</intervention_name>
    <description>Randomization to normal saline</description>
    <arm_group_label>Normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt; 18 years of age at the time of enrollment

          -  Patients presenting for right sided typical atrial flutter ablation who have a
             clinical indication to undergo catheter ablation

          -  Fully informed written informed consent by either the subject or subject's legal
             representative and ability for subject to comply with study responsibilities

        Exclusion Criteria:

          -  The presence of thrombus within the left atrial appendage

          -  Prior catheter ablation of the cavotricuspid isthmus for right sided atrial flutter

          -  The inability to provide consent or comply with study requirements

          -  A predicted life expectancy of &lt; 12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Benedict M. Glover, MD</last_name>
    <phone>4164806100</phone>
    <phone_ext>7383</phone_ext>
    <email>benedict.glover@sunnybrook.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benedict M. Glover, MD</last_name>
      <phone>4164806100</phone>
      <phone_ext>7383</phone_ext>
      <email>benedict.glover@sunnybrook.ca</email>
    </contact>
    <contact_backup>
      <last_name>Catherine Parry, BA, CHIM</last_name>
      <phone>4164804276</phone>
      <email>catherine.parry@sunnybrook.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 26, 2019</study_first_submitted>
  <study_first_submitted_qc>June 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2019</study_first_posted>
  <last_update_submitted>June 26, 2019</last_update_submitted>
  <last_update_submitted_qc>June 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sunnybrook Health Sciences Centre</investigator_affiliation>
    <investigator_full_name>Dr. Benedict Glover</investigator_full_name>
    <investigator_title>Staff electrophysiologist Schulich Heart Program, Associate Professor University of Toronto</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Flutter</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Multicentre study, patient data deidentified for post-enrolment analysis</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

